Patent intelligence · US
US 9956293
Targeted therapeutics
Targeted therapeutics
Patent details — US 9956293
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 1, 2018
- Expiration
- Apr 26, 2038
- Applicant
- Madrigal Pharmaceuticals, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K31/167, A61K31/337, A61K31/357
Quick answer
US 9956293 (Targeted therapeutics) is held by Madrigal Pharmaceuticals, Inc.. Status: granted. Granted May 1, 2018. Expires Apr 26, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Madrigal Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/167, A61K31/337, A61K31/357, A61K31/4184, A61K31/4196
More from Madrigal Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12377104
Methods for treating a fatty liver disease
granted -
US 11986481
Method of synthesizing thyroid hormone analogs and polymorphs thereof
granted -
US 11806353
Methods of treating liver disorders or lipid disorders with a THR-beta agonist
granted -
US 11564926
Methods of synthesizing thyroid hormone analogs and polymorphs thereof
granted -
US 11491145
Combination therapies comprising targeted therapeutics
granted -
US 11377447
Targeted therapeutics
granted -
US 11090308
Methods of treating liver disorders or lipid disorders with a THR-beta agonist
granted -
US 10894050
Methods of synthesizing thyroid hormone analogs and polymorphs thereof
granted
Frequently asked questions
What is US patent 9956293?
US 9956293 (Targeted therapeutics) is held by Madrigal Pharmaceuticals, Inc.. Status: granted. Granted May 1, 2018. Expires Apr 26, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9956293?
Madrigal Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.
When does US 9956293 expire?
Our index shows an expiration date of Apr 26, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.